Estrogen response element half-site (ERE half-site)

The estrogen response element (ERE) half-site is a specific DNA sequence, typically 5'-AGGTCA-3', that serves as a fundamental regulatory unit for estrogen-mediated gene expression [1]. These half-sites are recognized and bound by estrogen receptors (ERα and ERβ), which can function as monomers or as part of dimeric complexes to initiate or repress the transcription of target genes [2]. While a full ERE consists of two half-sites arranged as an inverted repeat, many estrogen-responsive genes contain isolated half-sites that are sufficient for receptor recruitment and transcriptional activity [1]. In diseases such as breast and endometrial cancer, the aberrant activation of ERs and their subsequent binding to ERE half-sites drive the proliferation of malignant cells [3]. Therapeutic intervention typically involves the use of selective estrogen receptor modulators (SERMs) or degraders (SERDs), which bind to the estrogen receptor and prevent its productive interaction with these DNA sites [3]. Consequently, while the DNA sequence itself is a critical component of the signaling pathway, it is the associated receptor protein that serves as the primary druggable target in clinical practice.

Other names

ERE half-siteEstrogen response element monomeric siteAGGTCA motifEstrogen receptor binding site

Inhibition of estrogen receptor-mediated transcription by blocking receptor binding to DNA response elements.